Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bastiaan M Privé

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|May 24, 2019
[Complications after intravesical BCG instillation]Bastiaan M Privé, H M Bruins, Bert Mulder, et al.
EJNMMI Physics|April 3, 2024
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CTDagmar Grob, Bastiaan M Privé, Constantijn H J Muselaers, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|December 6, 2024
Single-time-point dosimetry using model selection and the Bayesian fitting method: A proof of conceptBisma B Patrianesha, Steffie M B Peters, Deni Hardiansyah, et al.
Clinical Nuclear Medicine|March 2, 2022
89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CTFlorian Rosar, Mark Bartholomä, Stephan Maus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer PatientsMelline G M Schilham, Patrik Zamecnik, Bastiaan M Privé, et al.
EJNMMI Reports|November 26, 2024
[<sup>18</sup>F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [<sup>18</sup>F]FluciclovineCato C Loeff, Willemijn van Gemert, Bastiaan M Privé, et al.
Cancers|May 14, 2022
An Explorative Study of the Incidental High Renal Excretion of [<sup>18</sup>F]PSMA-1007 for Prostate Cancer PET/CT ImagingYoussra Allach, Amina Banda, Willemijn van Gemert, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 5, 2022
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimatesFlorian Rosar, Andrea Schaefer-Schuler, Mark Bartholomä, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 10, 2023
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of <sup>177</sup> Lu-PSMA-617 in prostate cancer patientsHinke Siebinga, Bastiaan M Privé, Steffie M B Peters, et al.
Nuclear Medicine Communications|January 4, 2023
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetryMaike J M Uijen, Bastiaan M Privé, Carla M L van Herpen, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Nederlands Tijdschrift Voor Geneeskunde|May 24, 2019
[Complications after intravesical BCG instillation]Bastiaan M Privé, H M Bruins, Bert Mulder, et al.
EJNMMI Physics|April 3, 2024
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CTDagmar Grob, Bastiaan M Privé, Constantijn H J Muselaers, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|December 6, 2024
Single-time-point dosimetry using model selection and the Bayesian fitting method: A proof of conceptBisma B Patrianesha, Steffie M B Peters, Deni Hardiansyah, et al.
Clinical Nuclear Medicine|March 2, 2022
89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CTFlorian Rosar, Mark Bartholomä, Stephan Maus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer PatientsMelline G M Schilham, Patrik Zamecnik, Bastiaan M Privé, et al.
EJNMMI Reports|November 26, 2024
[<sup>18</sup>F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [<sup>18</sup>F]FluciclovineCato C Loeff, Willemijn van Gemert, Bastiaan M Privé, et al.
Cancers|May 14, 2022
An Explorative Study of the Incidental High Renal Excretion of [<sup>18</sup>F]PSMA-1007 for Prostate Cancer PET/CT ImagingYoussra Allach, Amina Banda, Willemijn van Gemert, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 5, 2022
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimatesFlorian Rosar, Andrea Schaefer-Schuler, Mark Bartholomä, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 10, 2023
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of <sup>177</sup> Lu-PSMA-617 in prostate cancer patientsHinke Siebinga, Bastiaan M Privé, Steffie M B Peters, et al.
Nuclear Medicine Communications|January 4, 2023
Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetryMaike J M Uijen, Bastiaan M Privé, Carla M L van Herpen, et al.
Pageof 3